Conference abstract · 2022
Conference abstractPublished 14 Sep 2017
PDX modeling to generate drug-resistant tumors
Tufts Cummings School of Veterinary Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We developed a mouse avatar technology which involves capturing, expanding, characterizing and viably freezing primary patient tumors at low passage number to better model long-term treatment and recurrence of solid tumors as similar to the patient as possible. Through long-term dosing we are able to generate refractory tumor models resistant to normally efficacious drugs. Our process can take more than 100 days of treatment to generate drug-resistant models in vivo. Currently, we implant cells or tumor pieces sourced from patient-derived primary resection. These models are incredibly powerful when used for molecular profiling to better understand predictive markers of progressive, metastatic, refractory disease, and also empirically as tools for drug discovery. It is our belief that testing new cancer therapies being developed against the very same drug-resistant tumors they are most likely to face in early clinical trials will provide a new level of translational success to future oncology drug discovery programs and improve patient experience in clinical trials
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Oct 2017
Double rolling circle replication (DRCR): a mode of amplification of oncogene as well as drug-resistant genes and replication of HSV and chloroplast DNA
Conference abstract · 20 Oct 2014
7-Nitro-2,1,3-benzoxadiazoles, a promising strategy for drug-resistant tumors
Conference abstract · 16 Jul 2018
Docosahexaenoic acid prevents resistance to antiepileptic drugs in two animal models of drug-resistant epilepsy
Conference abstract
Tailored-pharmacophore model to enhance virtual screening and drug discovery: A case study on the identification of potential inhibitors against drug-resistant Mycobacterium tuberculosis (3R)-hydroxyacyl- ACP dehydratase
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectMathematics & Statistics
- SubjectOncology & Cancer
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Michael R. Briggs”